Nvidia investors took a steep dive recently, as it got engulfed in the recent tariffs turbulence. Read why I maintain my buy ...

Utah Medical Products' stock decline is overblown, as margins remain intact and the balance sheet has substantial assets.

Explore VERV's promising gene-editing therapies, including VERVE-102 with a 69% LDL-C reduction. Click here to read my most ...

Discover investment opportunities amid market uncertainty with a basket of recently selected stocks based on technical ...

FS KKR Capital trades at a 21% NAV discount, offering value for passive income investors. Click here to read an analysis of ...

MSTY is a single stock covered call ETF tied to Strategy, which is heavily linked to Bitcoin. Find out why I'm bearish on the ...

GXO Logistics faces macroeconomic pressures, integration challenges and soft 2025 growth. Read more about the company's ...

Republic Services outperforms with recession-resistant cash flows, strategic investments, and robust growth. Read more about ...

Nvidia Corporation navigates trade uncertainties amid fluctuating tariffs and AI regulations. Learn why it remains a Buy. Click for my NVDA stock update.

MGV has outperformed the S&P 500 in 2025, with a solid valuation and high-quality portfolio, making it a buy despite recent ...

Discover how we navigated surprises in Q1, updated our portfolio strategy, and reviewed performance, including insights on ...

Nvidia Corp. faces challenges, with new U.S. licensing rules cutting $5.5B from quarterly sales and China's demand declining.